Can a new iron strategy help kidney dialysis patients fight anemia?

NCT ID NCT06884280

Recruiting now Disease control Sponsor: Hull University Teaching Hospitals NHS Trust Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at different ways to give iron to people with kidney failure who are on peritoneal dialysis. Participants will get either high-dose or low-dose intravenous iron, or oral iron tablets. The main goal is to see if a larger trial is possible by checking how many people join, stay, and complete the study over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iron (intravenous iron isomaltoside 1000 or oral ferrous sulfate)
What this could lead to: If successful, this could help design a larger study to find the best way to treat anemia in people on peritoneal dialysis, potentially improving energy and quality of life.
What could go wrong: This is a small feasibility trial with only 30 participants, so results may not apply to everyone. It is testing whether a bigger study is possible, not yet proving which iron treatment works best.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia end stage renal failure iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAEMIA IRON DEFICIENCY ANAEMIA PERITONEAL DIALYSIS

Contacts and locations

Locations

Hull University Teaching Hospitals NHS Trust
RECRUITING

Hull, East Riding Of Yorkshire, HU3 2JZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.